Drug Type Chemical drugs |
Synonyms CTS 3497, CTS3497 |
Target |
Action inhibitors |
Mechanism PRMT5 inhibitors(Protein arginine methyltransferase 5 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Malignant Solid Neoplasm | Phase 2 | China | 25 Dec 2024 | |
| Lymphoma | Phase 2 | China | 24 Dec 2024 | |
| Methylthioadenosine phosphorylase deletion cancer | Phase 2 | China | 24 Dec 2024 | |
| Esophageal Carcinoma | Phase 1 | China | - | |
| Non-Small Cell Lung Cancer | Phase 1 | China | - | |
| Pancreatic Cancer | Phase 1 | China | - | |
| Advanced Lymphoma | IND Approval | China | 27 Nov 2024 | |
| Esophageal Squamous Cell Carcinoma | Preclinical | China | 17 Apr 2024 |





